title: [The advantages of Reprimum therapy in pulmonary sarcoidosis and other granulomatous diseases].
abstract: In sarcoidosis and other granulomatous non-caseous diseases, the election treatment is immunosuppressive, mainly with cortisones that ensure more than 70% lasting remissions. Continuous use of cortisones for a long time (8-30 months) in high doses leads to serious side effects: gastric and intestinal ulcers, obesity, osteoporosis, suprarenal dysfunction, sensitivity to infections. Good results and elimination of the important side effects were obtained by treatment with Reprimum--a semisynthetic antibiotic with a wide spectrum and immunosuppressive properties--administered alone or with prednisone in small doses (15-20 mg once) in 6 weeks' series: 2 weeks--Reprimum 10/mg/kg daily +/- prednisone and for other 4 weeks--Reprimum 15 mg/kg twice a week +/- prednisone followed by two weeks' break. In 75 patients with histopathologically confirmed sarcoidosis (of whom 7-9.3% with outside-the-lung situs, too), the treatment with Reprimum gave: 94.7% lasting remission, only 5.3% failures, reduction of the treatment period to 6-12 months and the absence of any important side reaction. In other 37 sarcoidosis cases, failures of cortisone therapy (of which 11-30% relapses after 2-6 years), the treatment with Reprimum together with prednisone allowed recovery of 29 patients (78.4%). The same treatment with Reprimum, used in 22 patients with immunosuppressive treatment indication (dermatomyositis, Kaposi's syndrome, thrombocytopenias, nodose periarteritis, silicosis), of whom 18 (81.8%) were failures of the cortisone therapy, healed 20 of these cases (90.9%). Reprimum immunosuppressive property acts at the level of T4+ lymphocyte, involved in sarcoidosis pathogenesis. The functional blockage of T4+ lymphocyte can be also achieved by cyclosporine A.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: C
authors.initials: C
authors.lastname: Anastasatu
authors.forename: A
authors.initials: A
authors.lastname: Albu
authors.forename: D
authors.initials: D
authors.lastname: Burnea
authors.forename: C
authors.initials: C
authors.lastname: Didilescu
authors.forename: V
authors.initials: V
authors.lastname: Gîrlonţa
authors.forename: P
authors.initials: P
authors.lastname: Mihălţan
authors.forename: N
authors.initials: N
authors.lastname: Popescu
authors.forename: A
authors.initials: A
authors.lastname: Savu
authors.forename: S
authors.initials: S
authors.lastname: Udrea
authors.forename: E
authors.initials: E
authors.lastname: Păunescu
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006099:Granuloma / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012294:Rifamycins / Q000627:therapeutic use*; D012507:Sarcoidosis / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D012294:Rifamycins; C062637:Reprimun; D011241:Prednisone
vernacular_title: Avantajele terapiei cu Reprimum în sarcoidoza pulmonară şi alte boli granulomatoase.